The ShcA adapter protein transmits activating signals downstream of receptor and cytoplasmic tyrosine kinases through the establishment of phosphotyrosine-dependent complexes. In this regard, ShcA possesses both a phosphotyrosine-binding domain (PTB) and Src homology 2 domain (SH2), which bind phosphotyrosine residues in a sequence-specific manner. Although the majority of receptor tyrosine kinases expressed in breast cancer cells bind the PTB domain, very little is known regarding the biological importance of SH2-driven ShcA signaling during mammary tumorigenesis. To address this, we employed transgenic mice expressing a mutant ShcA allele harboring a non-functional SH2 domain (ShcR397K) under the transcriptional control of the endogenous ShcA promoter. Using transplantation approaches, we demonstrate that SH2-dependent ShcA signaling within the mammary epithelial compartment is essential for breast tumor outgrowth, survival and the development of lung metastases. We further show that the ShcA SH2 domain activates the AKT pathway, potentially through a novel SH2-mediated complex between ShcA, 14-3-3z and the p85 regulatory subunit of phosphatidylinositol 3 (PI3 0 ) kinase. This study is the first to demonstrate that the SH2 domain of ShcA is critical for tumor survival during mammary tumorigenesis.
INTRODUCTION
The ShcA adapter protein integrates phosphotyrosine-dependent signals downstream of receptor and cytoplasmic tyrosine kinases through an N-terminal phosphotyrosine-binding domain (PTB), a C-terminal Src homology 2 domain (SH2) and three central tyrosine phosphorylation sites (Y239/Y240/Y317). In the breast cancer patients, increased ShcA signaling predicts nodal status, stage and relapse.
1 --2 High-ShcA levels further correlate with reduced CD8 þ T-cell infiltration and poor survival. 3 Transgenic mouse models have demonstrated that ShcA is critical for breast cancer progression. Loss of ShcA virtually ablates ErbB2-induced mammary tumor initiation. 3 --4 The ShcA pathway further contributes to tumor cell survival, angiogenesis, metastasis and immunosuppression in transgenic mouse models of the breast cancer. 3 --4 These observations define ShcA as a major signaling axis that contributes to the tumorigenic process.
Strikingly, the majority of receptor tyrosine kinases, which are expressed in breast cancer cells, bind the PTB domain of ShcA. 5 --13 The polyoma virus middle T oncogene (MT) is a well-characterized surrogate of receptor tyrosine kinase signaling that recapitulates many of the features associated with breast cancer progression, both at the molecular and histological level. 14 --15 MT also binds the PTB domain of ShcA and mutation of the ShcA-binding site (Y250F) impairs the incidence and severity of mammary tumorigenesis. 16 Overexpression of ShcA in MT-Y250F-expressing mammary epithelial cells accelerates tumor onset, 17 suggesting that the formation of other ShcA intracellular complexes partially compensates for loss of ShcA signaling downstream of the transforming oncogene.
Whereas the above studies suggest that ShcA is a critical signaling molecule during oncogene-induced tumor progression, the role of ShcA-associated proteins in this process is partially understood. Although in vitro and in vivo studies indicate that consensus Grb2-binding sites contribute to ShcA-driven mammary tumorigenesis, 4 the biological significance of the ShcA SH2 domain during breast cancer progression is unknown. We demonstrate that the ShcA SH2 domain is critical for breast cancer outgrowth and survival, primarily through activation of the AKT pathway. We further show that the ShcA SH2 domain recruits a 14--3--3z/p85a-PI3K (phosphatidylinositol 3-kinase) complex in breast cancer cells, which is known to confer a survival phenotype.
RESULTS AND DISCUSSION
We interbred MMTV/MT transgenic mice 14 with animals expressing a targeted ShcA allele, harboring a point mutation in the SH2 domain (R397K) that renders it unable to bind phosphotyrosine. The ShcR397K allele is expressed under the control of the endogenous ShcA promoter, which allows us to examine the importance of SH2-driven ShcA signaling at physiologically relevant levels. 18 We were unable to generate ShcA
homozygotes because of embryonic lethality. 18 Despite this fact, we observe a modest increase in the latency of tumor onset in MT/ShcA þ /R397K (herein referred to as MT/ShcR397K) females relative to MT controls ( Figure 1a ). We also demonstrate that mammary tumor outgrowth was significantly reduced in MT/ShcR397K mice, both at 4 and 6 weeks following first physical palpation of the primary tumor (Figure 1b) . Moreover, attenuated mammary tumor outgrowth is specific to the R397K mutation as the growth potential of mammary tumors is similar between control MT/ShcA þ / þ animals and those harboring one floxed wild-type ShcA knock-in allele (MT/ShcA þ /fl ) (Supplementary Figure 1) . Finally, we show that heterozygous expression of the ShcAR397K mutant not only delays the development of lung metastases but also reduces the number and size of metastatic lesions compared with MT controls (Figure 1c ). These observations demonstrate that the ShcA SH2 domain has a critical role during MT-induced mammary tumor growth, both at the primary site and in the metastatic setting.
We next compared the proliferative, apoptotic and angiogenic potential of MT and MT/ShcR397K tumors by performing Ki67, terminal deoxynucleotidyl transferase dUTP nick end labeling and CD31 immunohistochemical staining on control and ShcR397K-expressing tumors. Although the ShcA SH2 domain is dispensable for MT-induced tumor cell proliferation and endothelial recruitment ( Supplementary Figure 2) , we observed a robust and statistically significant increase in the percentage of apoptotic cells in MT/ShcR397K tumors at various times during mammary tumor outgrowth (Figures 2a and b) .
In order to characterize the mechanism through which the ShcA SH2 domain promotes a pro-survival phenotype, the activation status of key signaling pathways were determined. Although ERK activation is highly variable in MT and MT/ShcR397K tumors, we observe a dramatic reduction in AKT phosphorylation in MT/ ShcR397K tumors at 4 and 6 weeks post-palpation (Figures 2c and d) . These data suggest that the SH2 domain of ShcA engages signaling pathways that activate AKT and enhance tumor cell survival.
One complication in interpreting these observations arises from the fact that the ShcR397K mutant allele is germ line in nature. 18 Thus, SH2-mediated ShcA signaling is compromised both in the tumor epithelium and stromal cell types. To confirm that the ShcR397K mutant is acting in a cell autonomous fashion, we established cell lines from MT (#2186) and MT/ShcR397K (#9907) mammary tumors. Consistent with the transgenic studies, we observed that tumor outgrowth was impaired in breast cancer ) over all 10 mammary glands either at 4 or 6 weeks post-palpation (PP). The following number of animals were analyzed: MT (4 weeks), n ¼ 9; MT/ShcR397K (4 weeks), n ¼ 10; MT (6 weeks), n ¼ 13 and MT/ShcR397K (6 weeks), n ¼ 13. (c) At necropsy, all five lung lobes were fixed in 10% buffered formalin. Five step sections (50 microns) were subjected to H&E staining in order to quantify the number and size of lung metastatic lesions. Left panel: Incidence of lung metastases (upper graph): MT (4 weeks), n ¼ 6; MT/ShcR397K (4 weeks), n ¼ 13; MT (6 weeks), n ¼ 6 and MT/ShcR397K (6 weeks), n ¼ 14. Average number of lung lesions: MT (4 weeks), n ¼ 6; MT/ShcR397K (4 weeks), n ¼ 8; MT (6 weeks), n ¼ 6 and MT/ShcR397K (6 weeks), n ¼ 12 (middle graph). Average lung lesion area (mm 3 ): MT (4 weeks), n ¼ 6 mice/87 lesions; MT/ShcR397K (4 weeks), n ¼ 8 mice/69 lesions; MT (6 weeks), n ¼ 6 mice/502 lesions and MT/ShcR397K (6 weeks), n ¼ 12 mice/156 lesions (lower graph). Right panels: Representative H&E staining of lung metastases from the indicated genotypes at 4 and 6 weeks PP. Statistical analysis was performed using a two-tailed student's t-test. A previous study suggested that the ShcA SH2 domain binds Y179 of 14 --3 --3z and that retention of this tyrosine phosphorylation site is required to activate AKT downstream of the Granulocyte-macrophage colony-stimulating factor receptor. 19 To test this possibility, we employed a quantitative proteomics approach to identify intracellular proteins that specifically couple to the SH2 domain of ShcA. MT and MT/ShcR397K tumor lysates were first immunoprecipitated with anti-FLAG antibodies, which specifically bind the ShcR397K mutant. Wild-type ShcA was then sequentially purified from the same lysates using a ShcA-specific antibody, thus allowing us to directly examine the relative stoichiometry of interacting proteins in ShcA versus ShcR397K signaling complexes. Comparable amounts of protein were injected and analyzed by scheduled multiple reaction monitoring (sMRM)-based mass spectrometry. After normalization to ShcA levels, an equivalent amount of Grb2 was observed in ShcA-WT or ShcR397K protein complexes (Figures 4a and b ; Supplementary Table 1 ). This is expected given that the interaction between ShcA and Grb2 requires tyrosine phosphorylation sites within the ShcA CH1 domain. 20 --21 However, we observed a 10-fold reduction in the amount of 14 --3 --3 proteins that co-immunoprecipitated with the ShcA SH2 mutant (Figures 4a and b (c) At necropsy, the breast tumor material was flash frozen in liquid nitrogen and used to generate tumor cell lysates as previously described. 42 Immunoblot analysis on tumor cell lysates from the indicated genotypes at 4 and 6 weeks post-palpation using MT, 43 ShcA (610878; BD Biosciences, Mississauga, Ontario, Canada), ErbB2 (C18-Santa Cruz, Santa Cruz, CA, USA) pERK-(9101; Cell Signalling, Pickering, Ontario, Canada), ERK-(9102; Cell Signalling), pAKT-(9271; Cell Signalling), AKT-(9272; Cell Signalling) and Tubulin (T9026; Sigma, Oakville, Ontario, Canada) specific antibodies. Numbers indicate tumors derived from individual mice. (d) Quantification of the pAKT/AKT and pERK/ ERK ratios in tumor lysates from the indicated genotypes at 4 and 6 weeks post-palpation using Image J software (http://rsbweb.nih.gov/ij/ index.html). The data is representative of six independent MT and MT/ShcR397K mammary tumors for each time point. Statistical analysis was performed using a two-tailed student's t-test.
Supplementary Table 1 ). Given that 14 --3 --3 family proteins are highly homologous, the peptide identified by MRM analysis is shared by all 14 --3 --3 family members (Supplementary Figure 4) . Moreover, six of the 14 --3 --3 family members (b, e, g, Z, t and z) are similarly expressed, at the transcript level, in MT and MT/ ShcR397K expressing cells (Figure 4c ). Although 14 --3 --3s mRNA is reduced twofold in MT/ShcR397K-expressing cells (Figure 4c) , it has lost the consensus ShcA SH2-binding site ( Supplementary  Figure 4) , restores epithelial cell polarity in ErbB2-transformed mammary epithelial cells 22 and exerts tumor suppressive properties. 23 --24 Indeed, mammary tumors derived from ErbB2 transgenic mice frequently show loss of heterozygosity at the 14 --3 --3s locus. 25 Thus, 14 --3 --3s is not likely to participate in the activation of pro-survival signaling downstream of the ShcA SH2 domain. We further demonstrate that 14 --3 --3z specifically co-immunoprecipitates with wild-type ShcA, and not the ShcR397K mutant, in mammary tumor lysates, which is consistent with the observation that 14 --3 --3z activates the PI3K/AKT pathway by recruiting the p85 regulatory subunit 19, 26 (Figure 4d ). However, we cannot exclude the possibility that one or more of the remaining 14 --3 --3 family members are recruited to the SH2 domain of ShcA to enhance breast cancer cell survival.
Several studies demonstrate that ShcA is important for cancer cell survival. First, we demonstrated that germline expression of the ShcA-Y313F mutant delayed tumor onset and enhanced apoptosis in breast cancer transgenic mouse models. 4 However, this study could not discriminate between tumor epithelial versus stromal Y313 signaling in promoting tumor cell survival. Second, the ShcA Y239/Y240 phosphorylation sites induce Myc expression and suppress apoptosis within the hematopoietic lineage. 27 --28 Finally, previous studies demonstrate that the ShcA tyrosine phosphorylation sites also recruit Grb2/Gab complexes and activate the AKT pathway in IL3-stimulated hematopoietic cells. 29 However, the IL3 receptor beta subunit binds ShcA both through PTB-and SH2-dependent interactions, suggesting that the SH2 domain may be precluded from engaging PI3K. 30 Thus it is possible that ShcA has acquired redundant mechanisms, involving both the ShcA SH2 domain and the tyrosine phosphorylation sites, to amplify AKT activation.
Consistent with the importance of the PTB domain in mediating the association between ShcA and MT, 16, 31 the ShcA SH2 domain is dispensable to bind MT and Grb2 (Figure 4) . However, attenuated SH2-driven ShcA signaling increases apoptosis of MT-transformed cells (Figures 2 and 3 ). Thus we propose that the ShcA SH2 domain contributes to oncogene-induced activation of the PI3K/AKT pathway by recruiting the p85a regulatory subunit of PI3K, presumably via 14 --3 --3 dependent interactions. Importantly, the MT oncogene retains a consensus-binding site for the p85 subunit of PI3 0 kinase. Previous studies have shown that mutation of this p85-binding site (Y315/322F) significantly delayed MT-induced mammary tumor onset, resulting from increased rates of tumor cell apoptosis and reduced PI3K activation. 16 More recently, ErbB3 has also been shown to be essential for tumor onset, survival and activation of the AKT pathway in the MMTV/MT mouse model. 32 Importantly, although ErbB3 deletion or ablation of the p85-binding site in MT significantly delayed mammary tumor onset in MMTV/MT transgenic mice, attenuated SH2-driven ShcA signaling only modestly impaired tumor induction but significantly reduced tumor cell outgrowth. It is possible that these more modest effects on mammary tumor onset may result from ) were injected into the fourth mammary fat pad of Ncr nude mice (Taconic) as previously described. 45 Tumor outgrowth was monitored by weekly caliper measurements. The data are represented as tumor volumes (mm the fact that we were unable to generate MT/Shc R397K/R397K homozygous animals because of embryonic lethality. Regardless, these observations suggest that numerous pathways, including SH2-driven ShcA signaling, converge together downstream of oncogenic signals to amplify and sustain activation of the PI3K/ AKT pathway, leading to breast cancer cell survival.
We demonstrate that the ShcA SH2 domain exists in a molecular complex with 14 --3 --3z and the p85a subunit of PI3K in breast cancer cells (Figure 4e) . The 14 --3 --3 family consists of seven family members (b, z, e, g, Z, t and s) that exert both protumorigenic and tumor suppressive functions in cancer cells. 33 Several 14 --3 --3 family members have been reported to increase tumor survival through phospho-serine-dependent mechanisms that involve sequestration of the FOXO transcription factor and pro-apoptotic Bcl2 family members (BAD and BAX). 33 We propose a novel phospho-tyrosine-dependent mechanism by which 14 --3 --3 proteins increase tumor cell survival by recruiting the p85a regulatory subunit of PI3K. Although 14 --3 --3z co-immunoprecipitated with ShcA in tumor lysates, the 14 --3 --3 peptide identified by MRM analysis is common to all family members because of the high degree of conservation between these proteins (Supplementary Figure 4) . Moreover, all 14 --3 --3 family members contain two consensus-binding sites (pYXXM) for the SH2 domains of p85a-PI3K (Supplementary Figure 4) . 34 However, only 14 --3 --3b, z, e and t retain a consensus ShcA SH2-binding site (pY-I/E/Y/L-X-I/L) at this residue (Supplementary Figure 4) . 35 Among these proteins, 14 --3 --3e and t possess tumor suppressive functions by activating DNA damage checkpoints and blocking S phase entry. 36 --37 In contrast, 14 --3 --3b has been implicated in promoting tumorigenicity and metastasis of a hepatoma cell line. 38 Finally, 14 --3 --3z overexpression is associated with increased risk of recurrence and progression to invasive ductal carcinoma in breast cancer patients and promotes breast cancer cell survival. 39 --40 Moreover, the ShcA SH2 domain binds Y179 of 14 --3 --3z and mutation of the ShcAbinding site (Y179F) significantly reduced AKT activation and survival of a hematopoietic cell line. 19 Thus we propose that the ShcA SH2 domain binds tyrosine phosphorylation sites within 14 --3--3z, and potentially also 14 --3 --3b, to indirectly recruit p85a-PI3K to the plasma membrane, leading to activation of PI3 0 K/AKTmediated survival signaling responses. Future studies with mice carrying mutant members of 14 --3 --3 family should allow this issue to be addressed.
We suggest that the PTB domain of ShcA is primarily responsible for binding-activated receptor tyrosine kinases, which potentiates Grb2-dependent and -independent signaling through phosphorylation of the three major tyrosine residues in the CH1 domain. This study supports a role for the ShcA SH2 domain as a phosphotyrosine-dependent molecular scaffold that potentiates the formation of 14 --3 --3/PI3K complexes in breast cancer cells. This is consistent with the observation that tyrosine phosphorylation of ShcA induces a conformational change, which renders the SH2 domain able to participate in phosphotyrosine-dependent interactions. 41 This raises the intriguing possibility that the PTB domain initiates phospho-tyrosine dependent ShcA signaling and the SH2 domain functions to amplify and sustain pro-tumorigenic signaling responses. MT or MT/ ShcR397K tumor cell lysates were sequentially immunoprecipitated with anti-FLAG M2-agarose (A2220; Sigma) followed by a rabbit anti-ShcA polyclonal antibody (610082; BD Biosciences) pre-bound to protein A sepharose. Immunoprecipitates were subjected to on-bead tryptic digestion and dried peptides were reconstituted with 5% formic acid. MRM analysis was performed on a hybrid triple quadrupole/ion trap mass spectrometer (4000QTrap; ABI/MDS-Sciex, Foster City, CA, USA). Chromatographic separations of peptides were carried out on a nano-LC system (Eksigent, Concord, Ontario, Canada) coupled to a 100 mm i.d. fused silica column packed with 5 mm Zorbax C18 (Agilent, Mississauga, Ontario, Canada) as the trap column and a 75 mm i.d. fused silica column packed with 3.5 mm Zorbax C18 as the column. Peptides were separated with a linear gradient from 2 --30% acetonitrile over 90 min, at a flow rate of 300 nl/min. An in-house developed and validated scheduled MRM method, specifically designed for the detection and quantification of ShcA and its binding partners (Y Zheng, C Zhang, T Pawson, manuscript in preparation), was used to measure the relative abundance of ShcA, Grb2, p85a-PI3 0 K and 14 --3 --3 proteins in samples. A minimum of two peptides, with two transitions per peptide, was measured for each protein. A full MS/MS spectrum for each observed peptide was also acquired for sequence validation. Representative elution profiles of specific peptide ions are shown corresponding to the following peptides: ShcA (VEGGQLGGEEWTR), Grb2 (ESESAPGDFSLSVK), PI3K-p85a (NESLAQYNPK) and 14 --3 --3 (DSTLIMQLLR). (b) Levels of Grb2, PI3K-p85a and 14 --3 --3 in ShcA or ShcR397K-containing complexes is represented as the fold change of relative protein abundance (RA) from ShcR397K over wild-type ShcA immunoprecipitates (RA ShcR397K /RA ShcA ). RA for each protein is calculated as the mean derived from different transitions and peptides for each protein. Data is the representative of two biological replicates. Each biological sample was analyzed with a minimum of two technical repeats. Peak area (counts) for the transitions associated with specific peptides was quantified using MultiQuant v 1.2 (Applied Biosystems, Burlington, Ontario, Canada) software. (c) Total RNA was extracted from MT-2186 or MT/ShcR397-9907 breast cancer cell lines using Trizol reagent (Invitrogen, Burlington, Ontario, Canada) and subjected to qRT --PCR analysis using commercially available Taqman probes for each 14 --3 --3 family member (Mm01247811_m1, Mm00494242_m1, Mm00777369_m1, Mm00834297_m1, Mm01231061_g1, Mm01158416_g1 and Mm01180869_s1) (Applied Biosystems). The data is normalized to total GAPDH mRNA levels and is representative of three biological replicates and two technical replicates per cell line. (d) MT/ShcA þ /fl and MT/Shc þ /R397K tumors were lysed as previously described 42 and 2 mg total protein was immunoprecipitated with FLAG-agarose beads (ab1240; Abcam, Cambridge, MA, USA). Immunoblots and corresponding whole cell lysates (15 ug) were subjected to immunoblot analysis using ShcA (BD Biosciences) and 14 --3 --3z (Abcam)-specific antibodies. The increased amount of immunoprecipitated protein and the mobility shift in MT/ShcA þ /fl tumors reflects the fact that the wild-type ShcA allele in floxed-ShcA animals contains three FLAG epitope tags whereas the ShcR397K knock in mutant only contains one FLAG epitope tag. Each lane is identified by eartag numbers from the corresponding tumor bearing animals. (e) Wild-type ShcA and the ShcR397K mutant bind pY250 within the MT oncogene through the PTB domain. Moreover, both wild-type ShcA and the ShcR397K alleles are equally able to recruit Grb2 and activate the ERK pathway, thus leading to comparable rates of cell proliferation. However, wild-type ShcA, and not the SH2 mutant, recruits 14 --3 --3/PI3K-p85a to activate AKT and promote cell survival. All statistical analysis was performed using a two-tailed student's t-test.
